Pharmacological inhibition of IRAK4 kinase activity does not prevent cachexia in mice with pancreatic cancer

Abstract Background Inflammation is a hallmark of cachexia; however, effective anti‐inflammatory treatments have not yet been identified. Interleukin‐1 receptor‐associated kinase 4 (IRAK4) is a key signalling node linking interleukin‐1 receptor (IL‐1R) and toll‐like receptor (TLR) activation to the...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Shuxi Qiao, Brianna LaViolette, Brianna LaCarubba Paulhus, Xiangping Li, John Litchfield, Zhenhong Li, John C. Stansfield, Richard L. Gieseck III, Bei B. Zhang, Danna M. Breen
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Wiley 2023-07-01
Sarja:	JCSM Rapid Communications
Aiheet:	Anamorelin Inflammation IRAK4 Pancreatic cancer cachexia
Linkit:	https://doi.org/10.1002/rco2.85
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!